000			03187nam a22003735i 4500
001			81282
003			ES-MaUEC
005			20230207040322.0
007			cr nn 008mamaa
008			141128s2015 gw | s |||| 0|eng d
020			_a9783319115146
024	7		_a10.1007/978-3-319-11514-6 _2doi
050		4	_aRC547 _b.D784 2015
245	1	0	_aDrug Treatment of Sleep Disorders _cedited by Antonio Guglietta.
260			_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (VIII, 297 páginas) _b23 ilustraciones, 14 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aMilestones in Drug Therapy _x2296-6056
505	0		_aAn overview of sleep physiology and sleep regulation -- Neuronal networks regulating sleep and arousal: effect of drugs -- Classification of sleep disorders -- Development of new therapeutical agents for treatment of insomnia and other sleep disorders -- Low dose doxepin for insomnia -- Lorediplon: a new GABAa modulator drug for treatment of insomnia -- Zolpidem sublingual formulations -- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia -- Orexin/hypocretin antagonists in insomnia: from bench to clinic -- Modafinil and armodafinil -- Sodium oxybate (Xyrem®): a new and effective treatment for narcolepsy with cataplexy -- Cell therapy to treat narcolepsy -- Tasimelteon -- The past, present and future of drug development and treatment in sleep disorders.
520	3		_aFollowing reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGER, asignarmaterias_11febrero
650		0	_9139882 _aPsicofarmacología _0
650		7	_aNeurociencias _0 _2embne _9158907
650		7	_aFarmacología _0 _2embne _9137893
700	1		_aGuglietta, Antonio _eeditor literario _930993 _0comprobar BNE20002463140
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-11514-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12898727 _b10-10-17 _c18-01-16
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRC547 .D784 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11568343 _z06-04-17
999			_c81282 _d81282 _x1